# Cytokine Induced Memory-like NK Cell Adoptive Therapy for Relapsed AML After Allogeneic Hematopoietic Cell Transplant

> **NCT03068819** · PHASE1,PHASE2 · COMPLETED · sponsor: **Washington University School of Medicine** · enrollment: 62 (actual)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **DRUG:** CIML NK Cell Infusion
- **PROCEDURE:** CD3+ T Cell Product Infusion
- **PROCEDURE:** Leukapheresis

## Key facts

- **NCT ID:** NCT03068819
- **Lead sponsor:** Washington University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-10-23
- **Primary completion:** 2025-06-15
- **Final completion:** 2025-06-15
- **Target enrollment:** 62 (ACTUAL)
- **Last updated:** 2026-04-24

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03068819

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03068819, "Cytokine Induced Memory-like NK Cell Adoptive Therapy for Relapsed AML After Allogeneic Hematopoietic Cell Transplant". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03068819. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*